One sample. All the answers.

Reliable analyses of therapy-relevant genetic alterations for individualized cancer therapy

NEOliquid

Non-invasive blood test for molecular cancer diagnostics

Molecular cancer diagnostics in your laboratory

 

 

reliable


The hybrid capture-based NEO technology allows for the sensitive detection of clinically relevant point mutations, insertions, deletions, copy number alterations, trans­locations and micro­­satellite instability in a single sample: For reliable detection of genetic changes in routine clinical material.

certified


All our CE-IVD-compliant products include reagents for sample processing as well as bioinformatic data analysis. This enables the customer to carry out a comprehensive molecular tumor analysis in their laboratory - from sample preparation to medical diagnosis.

fast


Optimized processes for experimental procedures and data analysis enable fast diagnosis along with high data quality, and form the basis for a rational therapy decision.


NEOonsite

Molecular cancer diagnostics in your laboratory

NEO-Technology

Hybrid-capture-based next generation sequencing

Publications

Media, scientific publications and conference abstracts

Who we are

The founding and management team of New Oncology

Kontakt

Telephone

Office: +49.221.888.23 80

Address

NEO New Oncology GmbH
Gottfried-Hagen-Str. 20
51105 Cologne
Germany